RedHill生物制药公司收到纳斯达克关于最低股东权益不足的通知-动脉网

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

CISION 等信源发布 2025-04-18 04:01



可切换为仅中文







通知函目前不会对公司在纳斯达克资本市场的上市产生直接影响，公司收到通知函也不会影响其业务运营。

TEL AVIV, Israel

特拉维夫，以色列

and

和

RALEIGH, N.C.

罗利，北卡罗来纳州

，

April 17, 2025

2025年4月17日

/PRNewswire/ --

RedHill Biopharma Ltd.

红山生物制药有限公司

(Nasdaq:

（纳斯达克：

RDHL

) ('RedHill' or the 'Company'), a specialty biopharmaceutical company, today announced that the Company received a written notification (the 'Notification Letter') from the Listing Qualifications Department of the Nasdaq Stock Market LLC ('Nasdaq') dated

）（“RedHill”或“公司”），一家专业生物制药公司，今天宣布公司已收到纳斯达克股票市场有限责任公司（“纳斯达克”）上市资格部门发出的书面通知（“通知函”），日期为

April 15, 2025

2025年4月15日

, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1) (the 'Rule').

，通知公司其不再符合纳斯达克上市规则5550(b)(1)（“规则”）。

The Rule requires companies listed on the Nasdaq Capital Market to maintain a minimum of

该规则要求在纳斯达克资本市场上市的公司保持至少

$2,500,000

2500000美元

in stockholders' equity for continued listing. However, based on the Company's Annual Report on Form 20-F for the fiscal year ended

在股东权益方面符合持续上市的要求。然而，根据公司截至本财政年度末的20-F表格年度报告，

December 31, 2024

2024年12月31日

, filed on

，提交于

April 10, 2025

2025年4月10日

, the Company reported a stockholders' deficit of

，公司报告了股东赤字为

$4,683,000

4,683,000美元

, and does not meet the alternatives of market value of listed securities or net income from continuing operations, and is thus non-compliant with the Rule.

，并且不符合上市证券市值或持续经营业务净收入的替代标准，因此不符合该规则。

The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Letter. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until

通知函目前不会对公司在纳斯达克资本市场的上市地位产生直接影响，公司收到通知函也不会影响其业务运营。根据纳斯达克上市规则，公司有45个日历日，或直到

May 30, 2025

2025年5月30日

, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from receipt of the Notification Letter to evidence compliance.

，提交一份恢复合规的计划。如果计划被接受，纳斯达克可以自收到通知函之日起授予最多180个日历日的延期以证明合规。

The Company is looking into various options available to regain compliance and maintain its continued listing on the Nasdaq Capital Market. The Company intends to submit the compliance plan as soon as practicable. There can be no assurance that the Company's plan will be accepted or the Company will be able to regain compliance with the Rule..

公司正在研究各种可选方案，以重新遵守规定并保持其在纳斯达克资本市场的持续上市地位。公司打算尽快提交合规计划。无法保证公司的计划会被接受，或公司能够重新遵守该规定。

About RedHill Biopharma

关于RedHill生物制药公司

RedHill Biopharma Ltd. (Nasdaq:

RedHill 生物制药有限公司 (纳斯达克:

RDHL

) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug

）是一家专业生物制药公司，主要专注于美国胃肠道疾病、传染病和肿瘤学药物的开发和商业化。RedHill 推广 FDA 批准的胃肠道药物。

Talicia,

塔莉西亚，

for the treatment of

用于治疗

Helicobacter pylori (H. pylori)

幽门螺杆菌 (H. pylori)

infection in adults

成人感染

[1]

, with submission planned for marketing authorization in other territories. RedHill's key clinical late-stage development programs include: (i)

，计划在其他地区提交上市授权申请。RedHill的关键临床晚期开发项目包括：（i）

opaganib (ABC294640)

奥帕尼布 (ABC294640)

, a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications with U.S. Government and academic collaborations for development for radiation and chemical exposure indications such as Gastrointestinal-Acute Radiation Syndrome (GI-ARS), a Phase 2 study in prostate cancer in combination with Bayer's darolutamide and a Phase 2/3 program for hospitalized COVID-19 patients; (ii) .

首创的口服鞘氨醇激酶-2（SPHK2）选择性抑制剂，具有抗癌、抗炎和抗病毒活性，针对多种适应症，与美国政府和学术机构合作开发，用于辐射和化学物质暴露相关适应症，如胃肠急性辐射综合征（GI-ARS），与拜耳的达洛鲁胺联合用于前列腺癌的二期研究，以及针对住院新冠肺炎患者的二期/三期项目；（ii）。

RHB-204

, an all-in-one, fixed-dose, orally administered, combination antibiotic therapy with a planned Phase 2 study for Crohn's disease and Phase 3-stage for pulmonary nontuberculous mycobacterial (NTM) disease; (iii)

，一种集多种功能于一体的固定剂量口服复合抗生素疗法，计划进行克罗恩病的二期研究和肺非结核分枝杆菌（NTM）病的三期研究；（iii）

RHB-104

, with positive results from a first Phase 3 study for Crohn's disease; (iv)

，克罗恩病的首个第三阶段研究取得了积极成果；（四）

RHB-107

(

upamostat

向上移动

), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; and (v)

），一种口服广谱、宿主导向的丝氨酸蛋白酶抑制剂，具有应对大流行病的潜力，目前正处于晚期开发阶段，用于治疗未住院的症状性 COVID-19 患者，同时还针对多种其他癌症和炎症性胃肠道疾病；以及 (v)

RHB-102

, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside .

，可能在英国提交用于化疗和放疗引起的恶心和呕吐的申请，急性胃肠炎和胃炎的3期研究取得了积极结果，IBS-D的2期研究也取得了积极结果。RHB-102与Hyloris Pharma（EBR：HYL）合作，在全球范围内进行开发和商业化。

North America

北美

。

More information about the Company is available at

更多关于公司的信息，请访问

www.redhillbio.com

X.com/RedHillBio

。

Forward Looking Statements

前瞻性声明

This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的“前瞻性陈述”，可能讨论投资机会、股票分析、财务表现、投资者关系和市场趋势。这些陈述可能会以“打算”、“可能”、“将”、“计划”、“预期”、“预计”、“预测”、“估计”、“目标”、“相信”、“希望”、“潜力”或类似词语为前缀。

Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

前瞻性陈述基于某些假设，并受制于各种已知和未知的风险与不确定性，其中许多风险与不确定性超出公司的控制范围，无法预测或量化，因此，实际结果可能与这些前瞻性陈述所表达或暗示的结果有重大差异。

Such risks and uncertainties include, without limitation: market and other conditions; the Company's ability to regain and maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S.

此类风险和不确定性包括但不限于：市场及其他条件；公司重新获得并持续遵守纳斯达克资本市场上市要求的能力；新增收入产品或外部授权交易可能无法实现的风险；以及当前关于美国的不确定性风险。

government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and resu.

政府研发资金，且美国政府没有义务继续支持我们产品的开发，并可以随时停止此类支持；进入RNCP产品开发渠道或其他政府和非政府开发计划并不保证持续开发，也不能保证任何此类开发能够完成或取得成功；FDA可能不同意公司为其项目提出的开发计划；公司的开发计划和研究可能不成功，即使成功，此类研究和结果。

April 10, 2025

2025年4月10日

. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

本新闻稿中包含的所有前瞻性陈述仅截至本新闻稿发布之日作出。公司不承担更新任何书面或口头前瞻性陈述的义务，除非法律要求，无论是由于新信息、未来事件或其他原因。

Company contact:

公司联系方式：

Adi Frish

阿迪·弗里什

Chief Corporate and Business Development Officer

首席企业和业务发展官

RedHill Biopharma

红山生物制药公司

+972-54-6543-112

adi@redhillbio.com

Category: Corporate